Los Angeles Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $282K | Sell |
2,480
-61
| -2% | -$6.93K | ﹤0.01% | 1072 |
|
|
2025
Q1 | $267K | Sell |
2,541
-4,020
| -61% | -$423K | ﹤0.01% | 934 |
|
|
2024
Q4 | $703K | Sell |
6,561
-529
| -7% | -$56.7K | ﹤0.01% | 723 |
|
|
2024
Q3 | $710K | Sell |
7,090
-130
| -2% | -$13K | ﹤0.01% | 762 |
|
|
2024
Q2 | $608K | Buy |
+7,220
| New | +$608K | ﹤0.01% | 803 |
|
|
2021
Q3 | – | Sell |
-3,448
| Closed | -$282K | – | 1544 |
|
|
2021
Q2 | $282K | Sell |
3,448
-160
| -4% | -$13.1K | ﹤0.01% | 1414 |
|
|
2021
Q1 | $343K | Buy |
+3,608
| New | +$343K | ﹤0.01% | 1384 |
|
|
2020
Q3 | – | Sell |
-3,174
| Closed | -$221K | – | 1476 |
|
|
2020
Q2 | $221K | Buy |
+3,174
| New | +$221K | ﹤0.01% | 1375 |
|
|
2020
Q1 | – | Sell |
-6,508
| Closed | -$423K | – | 1419 |
|
|
2019
Q4 | $423K | Sell |
6,508
-10,452
| -62% | -$679K | ﹤0.01% | 1056 |
|
|
2019
Q3 | $1.05M | Buy |
16,960
+1,267
| +8% | +$78.7K | 0.01% | 794 |
|
|
2019
Q2 | $1.12M | Sell |
15,693
-6,012
| -28% | -$428K | 0.01% | 811 |
|
|
2019
Q1 | $1.7M | Buy |
21,705
+9,803
| +82% | +$769K | 0.01% | 699 |
|
|
2018
Q4 | $1.01M | Buy |
11,902
+4,190
| +54% | +$355K | 0.01% | 741 |
|
|
2018
Q3 | $1.32M | Buy |
7,712
+3,062
| +66% | +$524K | 0.01% | 777 |
|
|
2018
Q2 | $601K | Hold |
4,650
| – | – | ﹤0.01% | 1084 |
|
|
2018
Q1 | $479K | Buy |
4,650
+32
| +0.7% | +$3.3K | ﹤0.01% | 1044 |
|
|
2017
Q4 | $394K | Buy |
4,618
+1,906
| +70% | +$163K | ﹤0.01% | 1122 |
|
|
2017
Q3 | $230K | Buy |
+2,712
| New | +$230K | ﹤0.01% | 1217 |
|
|
2016
Q2 | – | Sell |
-3,092
| Closed | -$207K | – | 1265 |
|
|
2016
Q1 | $207K | Buy |
+3,092
| New | +$207K | ﹤0.01% | 1050 |
|